The chaos at Twitter has some surprising implications.
Flozins strike again!
If you missed the biggest NephJC of the year, at least read the highlights here.
The future for refractory lupus nephritis?
Ten Tweet round up of exciting CAR T trial in patients with SLE discussed last month - check it out while you can!
The EMPA-KIDNEY Visual Abstract
EMPA-Kidney: ‘Empa’sizing the role of Flozins in Chronic Kidney Disease
Keep Calm and #AskRenal
ASN Innovations in Kidney Education Contest winners
The 2022 NephJC Kidneys Award Winners
KidneyWk 2022 BINGO
Get the original #KidneyWk Bingo Board here (PDF).
We are not responsible if you get kicked out for yelling “BINGO!”
#KidneyWk is Here!
What does the future look like in ADPKD?
Basic science week - catch up in only Ten Tweets here.
Is the horse before the CAR T in SLE?
Is Anti-CD19 CAR T Cell therapy helpful in refractory SLE? The Visual Abract
Is Anti-CD19 CAR T Cell therapy an efficacious and tolerable option for refractory SLE?
NSMC intern Susan Thanabalasingam explains it graphically
mRNA cis-inhibition in PKD progression - The Visual Abstract
NSMC intern Sandhya Suresh simplifies the role of mRNA cis-inhibition in PKD progression via a lucid visual abstract
Role of mRNA cis-inhibition in PKD progression
2022 #NephJCKidneys vote begins
Announcing the 2022 #KidneyWk Logo
#NephJCKidneys are off to a cracking start
More diuretics = more diuresis
The ADVOR trial (adding acetazolamide in acute heart failure) is covered by #TenTweetNephJC